PROK on Nasdaq

PROKIDNEY CORP.

We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

$893.0KRevenue, fiscal 20252
-$69.0MNet income, fiscal 20252

Compare with Compass Therapeutics, Inc., ImageneBio, Inc. or Avalanche Biotechnologies, or pick any stock.

  • TickerPROK on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersWinston-Salem, North Carolina1
  • Incorporated inCayman Islands3
  • Business address2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, Nc 271033
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease (“CKD”) and diabetes. Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure to the preservation of kidney function. Our lead product candidate, rilparencel, is the only cell therapy in Phase 3 clinical study for the treatment of advanced CKD and type 2 diabetes. Rilparencel is a product that includes autologous Selected Renal Cells (“SRC”) prepared from a patient’s own (autologous) kidney cells. The SRC are formulated as rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure. Because rilparencel is a personalized product composed of cells prepared from a patient’s own …4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-18477.8%Operating margin2
-7725.2%Net margin2
1075.0%Revenue growth, 20252
-$135.3MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$114.1M
  • Interest0¢$4.0K
  • Income tax0¢$414.0K

Out of $893.0K in revenue.2 The company lost money this year.

Financial statements

Revenue52$893.0K in 2025
0$250.0K$500.0K$750.0K$1.0M2022: $0$020222023: $0$020232024: $76.0K$76.0K20242025: $893.0K$893.0K2025+1075%
Operating income6752-$165.0M in 2025+511% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$27.0M-$27.0M20202021: -$55.1M-$55.1M2021+104%2022: -$153.0M-$153.0M2022+178%2023: -$151.5M-$151.5M2023−1%2024: -$183.7M-$183.7M2024+21%2025: -$165.0M-$165.0M2025−10%
Net income6752-$69.0M in 2025+158% since 2020
-$150.0M-$100.0M-$50.0M02020: -$26.7M-$26.7M20202021: -$55.1M-$55.1M2021+106%2022: -$148.1M-$148.1M2022+169%2023: -$35.5M-$35.5M2023−76%2024: -$61.2M-$61.2M2024+73%2025: -$69.0M-$69.0M2025+13%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenue$893.0K$76.0K$0
Research and development$114.1M$127.7M$106.7M
General and administrative$51.8M$56.1M$44.8M
Total operating expenses$165.9M$183.8M$151.5M
Operating loss-$165.0M-$183.7M-$151.5M
Interest income$13.8M$19.8M$22.1M
Interest expense-$4.0K-$9.0K-$12.0K
Net loss before income taxes-$151.2M-$163.9M-$129.5M
Income tax (benefit) expense$414.0K-$598.0K$6.0M
Net loss before noncontrolling interest-$151.6M-$163.3M-$135.4M
Net loss attributable to noncontrolling interest-$82.6M-$102.1M-$100.0M
Net loss available to Class A ordinary shareholders-$69.0M-$61.2M-$35.5M

Compare PROKIDNEY CORP. with another company

Leadership

Who has led PROKIDNEY CORP., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Timothy Bertram2022–2023
  2. Bruce Culleton2023–now

Chief financial officer

  1. James Ryans2021
  2. James Coulston2022–now

Chief operating officer

  1. Deepak Jain2022–2023
2025
Board members and other officers (20)

Former names

  • Social Capital Suvretta Holdings Corp. IIIApr 21, 2021 to Jul 11, 20223

Timeline

  1. Dec 5, 2023New chief executive Bruce Culleton becomes CEO12
  2. Jul 13, 2022New chief executive Timothy Bertram becomes CEO13

Filings

370 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 67 major events, 144 insider forms, 36 large holders, 102 other. The latest 20:

  1. Aug 20, 20264 EDGAR
  2. Aug 18, 2026144 EDGAR
  3. Aug 18, 2026144 EDGAR
  4. Aug 12, 2026SCHEDULE 13G/A EDGAR
  5. Aug 10, 20268-K EDGAR
  6. Aug 10, 202610-Q EDGAR
  7. Aug 6, 20264 EDGAR
  8. Jul 6, 20264 EDGAR
  9. Jun 15, 20264 EDGAR
  10. Jun 10, 20263 EDGAR
  11. May 29, 20264 EDGAR
  12. May 29, 20264 EDGAR
  13. May 29, 20264 EDGAR
  14. May 29, 20264 EDGAR
  15. May 29, 20264 EDGAR
  16. May 29, 20264 EDGAR
  17. May 29, 20264 EDGAR
  18. May 29, 20268-K EDGAR
  19. May 15, 20268-K EDGAR
  20. May 15, 202610-Q EDGAR

The 370 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

66 open-market trades by officers, directors and large owners since October 2021: 17 buys and 49 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 20, 2026Pereira Brian JGDirectorSale250,000$1.42$355.0KForm 4
Aug 19, 2026Pereira Brian JGDirectorSale250,000$1.44$360.0KForm 4
Aug 18, 2026Pereira Brian JGDirectorSale257,164$1.37$352.3KForm 4
Nov 13, 2025Pereira Brian JGDirectorSale502,136$2.37$1.2MForm 4
Nov 12, 2025Pereira Brian JGDirectorSale255,026$2.72$693.7KForm 4
Jul 8, 2025Weber Darin J.Chief Regulatory OfficerSale103,480$3.02$312.5KForm 4
Apr 22, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy387,393$0.71$275.0KForm 4
Apr 17, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy25,000$0.75$18.8KForm 4
Apr 16, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy100,000$0.75$75.0KForm 4
Apr 15, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy468,000$0.70$327.6KForm 4
Apr 14, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy268,105$0.73$195.7KForm 4
Apr 11, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy1,900$0.61$1.2KForm 4
Apr 10, 2025Control Empresarial de Capitales S.A. de C.V.10% ownerBuy1,032,218$0.61$629.7KForm 4
Sep 19, 2024Weber Darin J.Chief Regulatory OfficerSale16,412$2.50$41.0KForm 4
Jul 26, 2024Weber Darin J.Chief Regulatory OfficerSale826$2.50$2.1KForm 4
Jun 18, 2024Weber Darin J.Chief Regulatory OfficerSale17,238$2.82$48.6KForm 4
Jun 13, 2024Legorreta Pablo G.DirectorBuy22,617,909$2.42$54.7MForm 4
Jun 11, 2024Control Empresarial de Capitales S.A. de C.V.10% ownerBuy8,264,462$2.42$20.0MForm 4
May 20, 2024Weber Darin J.Chief Regulatory OfficerSale17,238$4.08$70.3KForm 4
Apr 22, 2024Weber Darin J.Chief Regulatory OfficerSale16,438$2.51$41.3KForm 4

All 66 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 69. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Montanova Capital, LLC12,341,266$25.2M0.5%No change
Morgan Stanley9,854,178$20.1M0.0%+898,211
BlackRock, Inc.5,197,227$10.6M0.0%+3,810,111
Geode Capital Management, LLC2,390,147$4.9M0.0%+1,159,738
Bleichroeder LP2,000,000$4.1M0.7%No change
Hennion & Walsh Asset Management, Inc.1,847,749$3.8M0.1%+236,056
Artia Global Partners LP1,806,939$3.7M0.7%No change
Vanguard Capital Management LLC1,175,257$2.4M0.0%+28,320
Renaissance Technologies LLC1,099,400$2.2M0.0%−151,394
Millennium Management LLC1,054,705$2.2M0.0%−1,216,872
State Street Corp1,045,945$2.1M0.0%+489,100
Charles Schwab Investment Management Inc781,729$1.6M0.0%+153,958
UBS Group AG671,447$1.4M0.0%+336,901
Northern Trust Corp664,827$1.4M0.0%+423,247
MYDA Advisors LLC640,775$1.3M0.3%+212,000
Vanguard Fiduciary Trust Co632,149$1.3M0.0%+93,778
Bank Of America Corp /de/545,158$1.1M0.0%−208,254
Vanguard Portfolio Management LLC517,082$1.1M0.0%New
Voleon Capital Management LP473,307$965.5K0.0%+370,609
Amundi304,151$620.5K0.0%+12,443
Two Sigma Investments, LP273,259$557.4K0.0%−73,123
Susquehanna International Group, Llp252,906$515.9K0.0%+48,418
Goldman Sachs Group Inc203,006$414.1K0.0%−218,896
Virtus Investment Advisers, LLC199,510$407.0K0.1%+76,122
Bank of New York Mellon Corp176,657$360.4K0.0%+165,465

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43